{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:02:23Z","timestamp":1793775743661,"version":"4.6.1"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The Nipah virus (NiV), a highly deadly bat-borne paramyxovirus, poses a substantial threat due to recurrent outbreaks in specific regions, causing severe respiratory and neurological diseases with high morbidity. Two distinct strains, NiV-Malaysia (NiV-M) and NiV-Bangladesh (NiV-B), contribute to outbreaks in different geographical areas. Currently, there are no commercially licensed vaccines or drugs available for prevention or treatment. In response to this urgent need for protection against NiV and related <jats:italic>henipaviruses<\/jats:italic> infections, we developed a novel homotypic virus-like nanoparticle (VLP) vaccine co-displaying NiV attachment glycoproteins (G) from both strains, utilizing the self-assembling properties of ferritin protein. In comparison to the NiV G subunit vaccine, our nanoparticle vaccine elicited significantly higher levels of neutralizing antibodies and provided complete protection against a lethal challenge with NiV infection in Syrian hamsters. Remarkably, the nanoparticle vaccine stimulated the production of antibodies that exhibited superior cross-reactivity to homologous or heterologous <jats:italic>henipavirus<\/jats:italic>. These findings underscore the potential utility of ferritin-based nanoparticle vaccines in providing both broad-spectrum and long-term protection against NiV and emerging zoonotic <jats:italic>henipaviruses<\/jats:italic> challenges.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1387811","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:27:09Z","timestamp":1718134029000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["A highly effective ferritin-based divalent nanoparticle vaccine shields Syrian hamsters against lethal Nipah virus"],"prefix":"10.3389","volume":"15","author":[{"given":"Chunhong","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Feng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peipei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuekai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3201\/eid1012.040701","article-title":"Nipah virus encephalitis reemergence, Bangladesh","volume":"10","author":"Hsu","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04299-3","article-title":"Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia","volume":"354","author":"Chua","year":"1999","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3201\/eid1202.051247","article-title":"Nipah virus-associated encephalitis outbreak, Siliguri, India","volume":"12","author":"Chadha","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3201\/eid2102.141433","article-title":"Outbreak of henipavirus infection, Philippines, 2014","volume":"21","author":"Ching","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-02967-x","article-title":"Nipah virus outbreak: what scientists know so far","author":"Conroy","year":"2023","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01875-17","article-title":"Nipah virus infection","volume":"56","author":"Ang","year":"2018","journal-title":"J Clin Microbiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2011.10-0567","article-title":"Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission","volume":"85","author":"Halpin","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3201\/eid1705.100968","article-title":"Genomic characterization of Nipah virus, West Bengal, India","volume":"17","author":"Arankalle","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy612","article-title":"Outbreak investigation of nipah virus disease in kerala, India, 2018","volume":"219","author":"Arunkumar","year":"2019","journal-title":"J Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3201\/eid1508.081237","article-title":"Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007","volume":"15","author":"Luby","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"B11","volume-title":"Prioritizing diseases for research and development in emergency contexts","year":"2022"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5470.1432","article-title":"Nipah virus: a recently emergent deadly paramyxovirus","volume":"288","author":"Chua","year":"2000","journal-title":"Science."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3201\/eid1110.050513","article-title":"Genetic characterization of Nipah virus, Bangladesh, 2004","volume":"11","author":"Harcourt","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e2010","DOI":"10.1002\/rmv.2010","article-title":"Emerging trends of Nipah virus: A review","volume":"29","author":"Sharma","year":"2019","journal-title":"Rev Med Virol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3201\/eid1307.061128","article-title":"Person-to-person transmission of Nipah virus in a Bangladeshi community","volume":"13","author":"Gurley","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002024","article-title":"Comparison of the pathogenicity of Nipah virus isolates from Bangladesh and Malaysia\u00a0in the Syrian hamster","volume":"7","author":"DeBuysscher","year":"2013","journal-title":"PloS Negl Trop Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"30916","DOI":"10.1038\/srep30916","article-title":"Pathogenic differences between nipah virus Bangladesh and Malaysia strains in primates: implications for antibody therapy","volume":"6","author":"Mire","year":"2016","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2016.02.004","article-title":"Hendra virus ecology and transmission","volume":"16","author":"Field","year":"2016","journal-title":"Curr Opin Virol"},{"key":"B19","volume-title":"Summary of Hendra virus incidents in horses: Queensland Government","author":"Queensland","year":"2022"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3201\/eid0101.950107","article-title":"A novel morbillivirus pneumonia of horses and its transmission to humans","volume":"1","author":"Murray","year":"1995","journal-title":"Emerg Infect Dis"},{"key":"B21","volume-title":"Summary of human cases of Hendra virus infection: NSW Government","year":"2022"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30634-6","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study","volume":"20","author":"Playford","year":"2020","journal-title":"Lancet Infect Diseases."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3201\/eid2006.131022","article-title":"Novel Henipa-like virus, Mojiang Paramyxovirus, in rats, China, 2012","volume":"20","author":"Wu","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2202705","article-title":"A zoonotic henipavirus in febrile patients in China","volume":"387","author":"Zhang","year":"2022","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.3390\/pharmaceutics13101621","article-title":"Functionalizing ferritin nanoparticles for\u00a0vaccine development","volume":"13","author":"Rodrigues","year":"2021","journal-title":"Pharmaceutics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/path.4444","article-title":"Animal models of disease shed light on Nipah virus pathogenesis and transmission","volume":"235","author":"de Wit","year":"2015","journal-title":"J Pathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1177\/0192623312438738","article-title":"International harmonization of toxicologic pathology nomenclature: an overview and review of basic principles","volume":"40","author":"Mann","year":"2012","journal-title":"Toxicol Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.aivir.2016.12.001","article-title":"Zoonotic potential of emerging paramyxoviruses: knowns and unknowns","volume":"98","author":"Thibault","year":"2017","journal-title":"Adv Virus Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00005-14","article-title":"A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge","volume":"88","author":"Mire","year":"2014","journal-title":"J Virol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3201\/eid2003.131159","article-title":"Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health","volume":"20","author":"Middleton","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/1743-422X-10-237","article-title":"Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months","volume":"10","author":"Pallister","year":"2013","journal-title":"Virol J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"146ra07","DOI":"10.1126\/scitranslmed.3004241","article-title":"A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from\u00a0Nipah virus challenge","volume":"4","author":"Bossart","year":"2012","journal-title":"Sci Transl Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.06.015","article-title":"A\u00a0recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge","volume":"29","author":"Pallister","year":"2011","journal-title":"Vaccine."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.05.016","article-title":"A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats","volume":"26","author":"McEachern","year":"2008","journal-title":"Vaccine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01619-06","article-title":"Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine","volume":"80","author":"Mungall","year":"2006","journal-title":"J Virol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41541-021-00284-w","article-title":"A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus","volume":"6","author":"Geisbert","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00842","article-title":"Structure-based design of nipah virus vaccines: A generalizable approach to paramyxovirus immunogen development","volume":"11","author":"Loomis","year":"2020","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772864","article-title":"Chimeric fusion (F) and attachment (G) glycoprotein antigen delivery by mRNA as a candidate nipah vaccine","volume":"12","author":"Loomis","year":"2021","journal-title":"Front Immunol"},{"key":"B39","volume-title":"Moderna provides business update and announces three new development programs in infectious disease vaccines","year":"2021"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2200065119","article-title":"A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease","volume":"119","author":"Foster","year":"2022","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41541-019-0109-5","article-title":"Rabies-based vaccine induces potent immune responses against Nipah virus","volume":"4","author":"Rohan","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41541-022-00592-9","article-title":"ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys","volume":"7","author":"van Doremalen","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B43","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41541-023-00762-3","article-title":"Both chimpanzee adenovirus-vectored and DNA vaccines induced long-term immunity against Nipah virus infection","volume":"8","author":"Lu","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.175461","article-title":"Vaccines based on the Fusion protein consensus sequence protected Syrian hamsters from Nipah virus infection","volume":"8","author":"Lu","year":"2023","journal-title":"JCI\u00a0Insight"},{"key":"B45","unstructured":"WHO Target Product Profiles for Nipah virus Vaccines-Nipah virus-Vaccine-WHO-93452017"},{"key":"B46","doi-asserted-by":"publisher","first-page":"a002295","DOI":"10.1101\/cshperspect.a002295","article-title":"It's all about change: the antigen-driven initiation of B-cell receptor signaling","volume":"2","author":"Liu","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2003.08.004","article-title":"Repetitive versus monomeric antigen presentation: direct visualization of antibody affinity and specificity","volume":"143","author":"Baschong","year":"2003","journal-title":"J Struct Biol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","article-title":"Virus-like particle vaccinology, from bench to bedside","volume":"19","author":"Mohsen","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.790121","article-title":"Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases","volume":"12","author":"Tariq","year":"2021","journal-title":"Front Microbiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J Nanobiotechnology."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2019.1571871","article-title":"Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities","volume":"8","author":"Nie","year":"2019","journal-title":"Emerg Microbes Infect"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1387811\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:27:16Z","timestamp":1718134036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1387811\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2024.1387811"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1387811","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"article-number":"1387811"}}